Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMY109 in women with endometriosis
ISRCTN15654320Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of anti-IL-8 monoclonal antibody and desogestrel in endometriosis (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change in endometriosis severity by r-ASRM score. Started Jan 2024; status: active, not recruiting.
02
Drugs
anti-IL-8 monoclonal antibodydesogestrel
03
Conditions
endometriosis
Beyond the preview
Go deeper on ISRCTN15654320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15654320.